Royalty Pharma PLC (RPRX)

Royalty Pharma (RPRX) Stock Price & Analysis


RPRX Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$32.68 - $44.24
Previous Close$34.64
Average Volume (3M)1.79M
Market Cap
Enterprise Value$29.62B
Total Cash (Recent Filing)$2.43B
Total Debt (Recent Filing)$7.12B
Price to Earnings (P/E)306.8
May 04, 2023
0.77 (2.17%)
Share Statistics
EPS (TTM)0.11
Shares Outstanding443,166,030
10 Day Avg. Volume1,974,350
30 Day Avg. Volume1,794,491
Standard Deviation0.07
Financial Highlights & Ratios
Price to Book (P/B)2.98
Price to Sales (P/S)7.50
Price to Cash Flow (P/CF)7.70
P/FCF Ratio9.30
Enterprise Value/Market CapN/A
Enterprise Value/Revenue13.24
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda69.91
Price Target Upside34.74% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3



Risk Analysis

Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.



What was Royalty Pharma PLC’s price range in the past 12 months?
Royalty Pharma PLC lowest stock price was $32.68 and its highest was $44.23 in the past 12 months.
    What is Royalty Pharma PLC’s market cap?
    Currently, no data Available
    When is Royalty Pharma PLC’s upcoming earnings report date?
    Royalty Pharma PLC’s upcoming earnings report date is May 04, 2023 which is in 44 days.
      How were Royalty Pharma PLC’s earnings last quarter?
      Royalty Pharma PLC released its earnings results on Feb 15, 2023. The company reported $1.558 earnings per share for the quarter, beating the consensus estimate of $1.472 by $0.086.
        Is Royalty Pharma PLC overvalued?
        According to Wall Street analysts Royalty Pharma PLC’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does Royalty Pharma PLC pay dividends?
          Royalty Pharma PLC pays a Quarterly dividend of $0.2 which represents an annual dividend yield of 2.17%. See more information on Royalty Pharma PLC dividends here
            What is Royalty Pharma PLC’s EPS estimate?
            Royalty Pharma PLC’s EPS estimate is $0.83.
              How many shares outstanding does Royalty Pharma PLC have?
              Royalty Pharma PLC has 443,166,020 shares outstanding.
                What happened to Royalty Pharma PLC’s price movement after its last earnings report?
                Royalty Pharma PLC reported an EPS of $1.558 in its last earnings report, beating expectations of $1.472. Following the earnings report the stock price went down -0.291%.
                  Which hedge fund is a major shareholder of Royalty Pharma PLC?
                  Among the largest hedge funds holding Royalty Pharma PLC’s share is Viking Global Investors LP. It holds Royalty Pharma PLC’s shares valued at 396M.


                    Royalty Pharma Stock Smart Score

                    The Royalty Pharma stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                    Learn more about TipRanks Smart Score

                    Company Description

                    Royalty Pharma PLC

                    New York-based Royalty Pharma Plc is a biopharmaceutical company, which is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry.


                    Forecast EPS vs Actual EPS

                    Similar Stocks
                    Price & Change
                    Eli Lilly & Co
                    Merck & Company
                    Bristol Myers

                    Popular Stocks

                    What's Included in PREMIUM?
                    Make informed decisions based on Top Analysts' activity
                    Know what industry insiders are buying
                    Get actionable alerts from top Wall Street Analysts
                    Find out before anyone else which stock is going to shoot up
                    Get powerful stock screeners & detailed portfolio analysis